Masimo Co. (NASDAQ:MASI) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp reduced its stake in Masimo Co. (NASDAQ:MASI) by 15.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 610 shares of the medical equipment provider’s stock after selling 113 shares during the period. Fifth Third Bancorp’s holdings in Masimo were worth $101,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MASI. UMB Bank n.a. raised its position in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont purchased a new stake in shares of Masimo during the fourth quarter worth approximately $33,000. NBC Securities Inc. increased its stake in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 73 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 200 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Masimo by 136.5% in the fourth quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after acquiring an additional 269 shares during the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Stock Performance

Shares of MASI opened at $174.23 on Friday. The company’s 50 day simple moving average is $171.28 and its 200-day simple moving average is $144.71. The firm has a market cap of $9.33 billion, a PE ratio of 120.16 and a beta of 1.01. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $183.14. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same period last year, the firm posted $0.63 EPS. Masimo’s revenue for the quarter was up 5.4% on a year-over-year basis. As a group, equities analysts predict that Masimo Co. will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

MASI has been the topic of a number of analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. BTIG Research raised their price target on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Piper Sandler upped their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Wells Fargo & Company raised their target price on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Masimo presently has an average rating of “Moderate Buy” and a consensus price target of $191.40.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.